We are live on ! Find out more

State Street SPDR S&P Pharmaceuticals ETF

XPH

Market cap $597M

68.58 USD

+1.07

1.58%

At close Updated Sep 14, 12:49 PM EDT

1 day

1.58%

5 days

-2.57%

1 month

-3.38%

3 months

13.71%

6 months

27.52%

Year to date

24.22%

1 year

49.09%

5 years

44.93%

10 years

52.2%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 14.3%

Neutral 71.4%

Negative 14.3%

The Motley Fool

IXJ vs XPH: Global Healthcare ETF or Pharma Focus?

iShares Global Healthcare ETF provides broad sector coverage with a higher dividend yield than State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF has delivered stronger total returns over the last year but experiences significantly higher maximum drawdowns.

IXJ vs XPH: Global Healthcare ETF or Pharma Focus?

The Motley Fool

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

The Vanguard Health Care ETF offers a significantly lower expense ratio and a higher dividend yield than the State Street SPDR S&P Pharmaceuticals ETF. The State Street SPDR S&P Pharmaceuticals ETF provides concentrated exposure to drug manufacturers, while the Vanguard Health Care ETF covers a broader range of medical services and equipment.

Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH

The Motley Fool

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Fidelity MSCI Health Care Index ETF offers a lower expense ratio of 0.08% compared to the 0.35% charged by State Street SPDR S&P Pharmaceuticals ETF. State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry, whereas Fidelity MSCI Health Care Index ETF tracks the broader healthcare sector.

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH?

Schaeffers Research

Ditch These Historic ETF September Underperformers

Subscribers to Chart of the Week received this commentary on Sunday, Sept.

Ditch These Historic ETF September Underperformers

The Motley Fool

XPH vs PJP: Which Pharma ETF Offers Better Value

The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more concentrated portfolio of 29 stocks and lower price volatility as measured by beta.

XPH vs PJP: Which Pharma ETF Offers Better Value

The Motley Fool

Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH

The Invesco S&P 500 Equal Weight Health Care ETF provides broad exposure to the sector, while the State Street SPDR S&P Pharmaceuticals ETF focuses specifically on the pharmaceutical industry. The State Street SPDR S&P Pharmaceuticals ETF has significantly outperformed over the last year, though it carries higher concentration risk and historical volatility.

Better Healthcare ETF: State Street's Pharmaceuticals-Focused XPH vs. Invesco's S&P 500-Targeted RSPH

Zacks Investment Research

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

The State Street SPDR S&P Pharmaceuticals ETF (XPH) made its debut on 06/19/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.

Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Zacks Investment Research

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the State Street SPDR S&P Pharmaceuticals ETF (XPH)?

Healthcare Rules State Street's Top 5 ETFs in Past Month

With well over 170 ETFs on the market covering diverse investment strategies, State Street offers a prime window into which funds — and market trends — are leading the pack in the near term. Key Takeaways: Across State Street's 170+ ETFs, the top five performers this past month are all tied to the healthcare industry.

Healthcare Rules State Street's Top 5 ETFs in Past Month

The Motley Fool

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?

The iShares U.S. Pharmaceuticals ETF is larger by assets under management and offers a higher trailing dividend yield. The State Street SPDR S&P Pharmaceuticals ETF has delivered higher one-year returns but experienced a much steeper maximum drawdown over five years.

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?

See News Rankings

Price charts implemented using Lightweight Charts™